# Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis

Article · Arun Jayant Sanyal, Philip Noel Newsome, Iris Kliers, Laura Østergaard, Michelle T. Long, Mette Skalshøi Kjær, Anna M.G. Cali, Elisabetta Bugianesi, Mary Eugenia Rinella, Michael Roden, Vlad Ratziu

- Archive id: doi:10.1056/nejmoa2413258
- Published: 2025-04-30
- Venue: New England Journal of Medicine
- DOI: https://doi.org/10.1056/nejmoa2413258
- PMID: 40305708
- Citations: 1,106
- Source URL: https://doi.org/10.1056/nejmoa2413258
- PDF: https://iris.unito.it/bitstream/2318/2092070/2/Sanyal_NEJMoa2413258.pdf
- Provenance: openalex

_Abstract not reproduced: its license does not permit redistribution. See the source URL._

Topics: [GLP-1 & Incretin Therapies](https://space-kitty.com/topics/glp1-metabolic)

Cited in dossiers:
- [GLP-1 & Incretin Therapies: State of the Field (October 2026)](https://space-kitty.com/dossiers/glp1-metabolic)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.